Answers are grounded in this paper and cite their sources.
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib demonstrates a marked response in non-small cell lung cancer (NSCLC) positive for EGFR mutations. Co-mutations in the tumor-suppressor gene TP53 are associated with early resistance to EGFR-TKIs. Gain-of-function (GOF) mutations in TP53 not only abrogate its tumor-suppressor function but also manifest oncogenic properties that drive tumor progression. We previously found that osimertinib activated tumor necrosis factor-α–nuclear factor kappa B (TNF-α–NF-κB) signaling in TP53 GOF-mutant cells, thereby promoting early development of resistance to osimertinib, and that concurrent treatment with the TNF-α inhibitor infliximab restored osimertinib sensitivity in such resistant cells in mouse models. Based on these findings, we have designed an investigator-initiated single-arm study (REGAIN) to evaluate the efficacy of osimertinib plus infliximab therapy in patients with EGFR -mutant NSCLC harboring TP53 GOF mutations who have acquired resistance to osimertinib. Methods Patients with EGFR -mutant NSCLC harboring TP53 GOF mutations who developed resistance to osimertinib and prior platinum-based regimens, aged 18 years or older with a performance status of 0 or 1, receive combination therapy with osimertinib and infliximab. The primary endpoint is the objective response rate assessed by an independent review committee. The sample size ( n = 21) was calculated assuming a threshold response rate of 20% and an expected response rate of 45% Results Recruitment began in June 2025 and is ongoing. No efficacy or safety data are available. Conclusion This is the first prospective study focusing on cytokine inhibition as a strategy to overcome resistance to EGFR-TKIs.
No takes yet. Share an insight, caveat, or question.
Iwama et al. (2026) studied this question.